The Single Nucleotide Polymorphism IVS 1 + 309 in Mouse Double Minute 2 Does Not Affect Risk of Familial Breast Cancer
暂无分享,去创建一个
P. Bugert | K. Hemminki | A. Meindl | R. Schmutzler | B. Burwinkel | A. Försti | M. Untch | B. Wappenschmidt | C. Bartram | J. L. Bermejo | R. Klaes | S. Wilkening
[1] D. Eccles,et al. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. , 2006, Cancer letters.
[2] C. Bonaïti‐pellié,et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome , 2005, Journal of Medical Genetics.
[3] Sandya Liyanarachchi,et al. p53 Codon 72 and MDM2 SNP309 Polymorphisms and Age of Colorectal Cancer Onset in Lynch Syndrome , 2005, Clinical Cancer Research.
[4] L. Aaltonen,et al. The MDM2 promoter polymorphism SNP309T→G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck , 2005, Journal of Medical Genetics.
[5] A. Levine,et al. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. , 2005, Cancer research.
[6] Ruiwen Zhang,et al. p53-independent activities of MDM2 and their relevance to cancer therapy. , 2005, Current cancer drug targets.
[7] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[8] D. Easton,et al. EMGM Abstracts , 2003, Genetic epidemiology.
[9] R. Wooster,et al. Breast and ovarian cancer. , 2003, The New England journal of medicine.
[10] J. Peto,et al. The future of association studies of common cancers , 2003, Human Genetics.
[11] M. Oren,et al. The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.
[12] A. Meindl,et al. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population , 2002, International journal of cancer.
[13] J. Varley,et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations , 2001, Oncogene.
[14] W D Plummer,et al. Power and sample size calculations for studies involving linear regression. , 1998, Controlled clinical trials.
[15] D. Carney,et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.
[16] A. Levine,et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.
[17] K. Hemminki,et al. A population-based assessment of the clustering of breast cancer in families eligible for testing of BRCA 1 and BRCA 2 mutations , 2005 .
[18] B. Quesnel,et al. MDM2 gene amplification in human breast cancer. , 1994, European journal of cancer.